Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina Journal Article

Local Library Link: Find It @ Loyola

Authors: Payne, A. J.; Kaja, S.; Naumchuk, Y.; Kunjukunju, N.; Koulen, P.
Article Title: Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina
Abstract: The molecular pathways contributing to visual signal transduction in the retina generate a high energy demand that has functional and structural consequences such as vascularization and high metabolic rates contributing to oxidative stress. Multiple signaling cascades are involved to actively regulate the redox state of the retina. Age-related processes increase the oxidative load, resulting in chronically elevated levels of oxidative stress and reactive oxygen species, which in the retina ultimately result in pathologies such as glaucoma or age-related macular degeneration, as well as the neuropathic complications of diabetes in the eye. Specifically, oxidative stress results in deleterious changes to the retina through dysregulation of its intracellular physiology, ultimately leading to neurodegenerative and potentially also vascular dysfunction. Herein we will review the evidence for oxidative stress-induced contributions to each of the three major ocular pathologies, glaucoma, age-related macular degeneration, and diabetic retinopathy. The premise for neuroprotective strategies for these ocular disorders will be discussed in the context of recent clinical and preclinical research pursuing novel therapy development approaches.
Journal Title: International journal of molecular sciences
Volume: 15
Issue: 2
ISSN: 1422-0067; 1422-0067
Publisher: Unknown  
Journal Place: Switzerland
Date Published: 2014
Start Page: 1865
End Page: 1886
Language: ENG
DOI/URL:

10.3390/ijms15021865
Notes: LR: 20161019; GR: P01 AG022550/AG/NIA NIH HHS/United States; GR: P01 AG027956/AG/NIA NIH HHS/United States; GR: AG010485/AG/NIA NIH HHS/United States; GR: R01 EY014227/EY/NEI NIH HHS/United States; GR: AG022550/AG/NIA NIH HHS/United States; GR: P01 AG010485/AG/NIA NIH HHS/United States; GR: EY014227/EY/NEI NIH HHS/United States; GR: R01 EY022774/EY/NEI NIH HHS/United States; GR: EY022774/EY/NEI NIH HHS/United States; GR: RR022570/RR/NCRR NIH HHS/United States; GR: AG027956/AG/NIA NIH HHS/United States; GR: S10 RR027093/RR/NCRR NIH HHS/United States; GR: S10 RR022570/RR/NCRR NIH HHS/United States; GR: RR027093/RR/NCRR NIH HHS/United States; JID: 101092791; 0 (Antioxidants); 0 (Neuroprotective Agents); OID: NLM: PMC3958826; 2013/11/12 [received]; 2014/01/18 [revised]; 2014/01/21 [accepted]; epublish
LUC Authors
  1. Simon Kaja
    39 Kaja
Related LUC Article